CN102349889A - 一种含有决奈达隆的组合物 - Google Patents
一种含有决奈达隆的组合物 Download PDFInfo
- Publication number
- CN102349889A CN102349889A CN201110340013XA CN201110340013A CN102349889A CN 102349889 A CN102349889 A CN 102349889A CN 201110340013X A CN201110340013X A CN 201110340013XA CN 201110340013 A CN201110340013 A CN 201110340013A CN 102349889 A CN102349889 A CN 102349889A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- dronedarone
- acid
- composition according
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 229960002084 dronedarone Drugs 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 238000002425 crystallisation Methods 0.000 claims abstract description 10
- 230000008025 crystallization Effects 0.000 claims abstract description 10
- 239000003112 inhibitor Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 150000003904 phospholipids Chemical class 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229960003943 hypromellose Drugs 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 8
- 229940083466 soybean lecithin Drugs 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 6
- 108010000912 Egg Proteins Proteins 0.000 claims description 6
- 241000287828 Gallus gallus Species 0.000 claims description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 6
- 235000015165 citric acid Nutrition 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 210000004681 ovum Anatomy 0.000 claims description 6
- 239000011975 tartaric acid Substances 0.000 claims description 6
- 235000002906 tartaric acid Nutrition 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical group OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 39
- 229940079593 drug Drugs 0.000 abstract description 17
- 239000008187 granular material Substances 0.000 abstract description 9
- 239000002775 capsule Substances 0.000 abstract description 6
- 238000004090 dissolution Methods 0.000 abstract description 5
- 239000003826 tablet Substances 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 235000020937 fasting conditions Nutrition 0.000 abstract 1
- 229940126701 oral medication Drugs 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 13
- 239000008108 microcrystalline cellulose Substances 0.000 description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 12
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 12
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 235000012239 silicon dioxide Nutrition 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
- 239000008101 lactose Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000008213 purified water Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 238000005550 wet granulation Methods 0.000 description 7
- 239000000080 wetting agent Substances 0.000 description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 229940086972 dronedarone 400 mg Drugs 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical class [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 229920001992 poloxamer 407 Polymers 0.000 description 4
- 229940044476 poloxamer 407 Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 229960005260 amiodarone Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229950005770 hyprolose Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- -1 propoxyl group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LZOZLBFZGFLFBV-UHFFFAOYSA-N sulfene Chemical compound C=S(=O)=O LZOZLBFZGFLFBV-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
成分 | mg | % |
盐酸决奈达隆 | 426(相当于决奈达隆400mg) | 65.5 |
微晶纤维素 | 94 | 14.5 |
乳糖 | 27 | 4.2 |
枸橼酸 | 4 | 0.62 |
共聚维酮S630 | 20 | 3 |
低取代羟丙纤维素 | 32.5 | 5 |
蛋黄卵磷脂 | 40 | 6.2 |
二氧化硅 | 3.25 | 0.5 |
硬脂酸镁 | 3.25 | 0.5 |
纯化水 | 适量(在工艺过程中除去) | |
总计 | 650 | 100 |
成分 | mg | % |
盐酸决奈达隆 | 426(相当于决奈达隆400mg) | 42.6 |
微晶纤维素 | 339 | 33.9 |
枸橼酸 | 40 | 4 |
羟丙甲纤维素 | 80 | 8 |
交联羧甲基纤维素钠 | 80 | 8 |
蛋黄卵磷脂 | 2 | 2 |
二氧化硅 | 5 | 0.5 |
硬脂酸镁 | 10 | 1 |
总计 | 1000 | 100 |
成分 | mg | % |
盐酸决奈达隆 | 426(相当于决奈达隆400mg) | 65.54 |
微晶纤维素 | 65 | 10 |
乳糖 | 30.29 | 4.66 |
酒石酸 | 19.5 | 3 |
羟丙甲纤维素 | 65 | 10 |
交联聚维酮 | 32.5 | 5 |
大豆卵磷脂 | 5.2 | 0.8 |
二氧化硅 | 3.25 | 0.5 |
硬脂酸镁 | 3.25 | 0.5 |
5%羟丙甲纤维素水溶液 | 适量(水在工艺过程中除去) | |
总计 | 650 | 100 |
成分 | mg | % |
盐酸决奈达隆 | 426(相当于决奈达隆400mg) | 65.54 |
微晶纤维素 | 130 | 20 |
乳糖 | 55 | 8.46 |
交联聚维酮 | 32.5 | 5 |
二氧化硅 | 3.25 | 0.5 |
硬脂酸镁 | 3.25 | 0.5 |
纯化水 | 适量(在工艺过程中除去) | |
总计 | 650 | 100 |
成分 | mg | % |
盐酸决奈达隆 | 426(相当于决奈达隆400mg) | 65.54 |
微晶纤维素 | 130 | 20 |
乳糖 | 49.8 | 7.66 |
交联羧聚维酮 | 32.5 | 5 |
大豆卵磷脂 | 5.2 | 0.8 |
二氧化硅 | 3.25 | 0.5 |
硬脂酸镁 | 3.25 | 0.5 |
纯化水 | 适量(在工艺过程中除去) | |
总计 | 650 | 100 |
成分 | mg | % |
盐酸决奈达隆 | 426(相当于决奈达隆400mg) | 65.54 |
微晶纤维素 | 78 | 12 |
乳糖 | 36.8 | 5.66 |
羟丙甲纤维素 | 65 | 10 |
交联聚维酮 | 32.5 | 5 |
大豆卵磷脂 | 5.2 | 0.8 |
二氧化硅 | 3.25 | 0.5 |
硬脂酸镁 | 3.25 | 0.5 |
纯化水 | 适量(在工艺过程中除去) | |
总计 | 650 | 100 |
Tmax(h) | Cmax(ng/ml) | AUC(0-t)(hr*ng/ml) | |
实施例3禁食 | 3.33 | 220.28 | 2118 |
实施例3进食 | 2.0 | 238.63 | 2027 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110340013 CN102349889B (zh) | 2011-11-01 | 2011-11-01 | 一种含有决奈达隆的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110340013 CN102349889B (zh) | 2011-11-01 | 2011-11-01 | 一种含有决奈达隆的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102349889A true CN102349889A (zh) | 2012-02-15 |
CN102349889B CN102349889B (zh) | 2013-08-28 |
Family
ID=45573608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110340013 Active CN102349889B (zh) | 2011-11-01 | 2011-11-01 | 一种含有决奈达隆的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102349889B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103054820A (zh) * | 2012-08-22 | 2013-04-24 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸决奈达隆药物组合物及其制备方法 |
CN105412027A (zh) * | 2015-11-13 | 2016-03-23 | 青岛市海慈医疗集团 | 一种盐酸决奈达隆片剂的制备方法 |
CN108042489A (zh) * | 2017-12-19 | 2018-05-18 | 佛山市弘泰药物研发有限公司 | 一种盐酸决奈达隆自微乳制剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1267217A (zh) * | 1997-06-23 | 2000-09-20 | 萨诺菲-合成实验室公司 | 含苯并呋喃衍生物的固体药物组合物 |
CN101152154A (zh) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | 盐酸决奈达隆口服药物组合物及其制备方法 |
CN102188417A (zh) * | 2010-03-19 | 2011-09-21 | 江苏恒瑞医药股份有限公司 | 决奈达隆药物组合物 |
WO2011132167A1 (en) * | 2010-04-21 | 2011-10-27 | Sanofi-Aventis | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same |
-
2011
- 2011-11-01 CN CN 201110340013 patent/CN102349889B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1267217A (zh) * | 1997-06-23 | 2000-09-20 | 萨诺菲-合成实验室公司 | 含苯并呋喃衍生物的固体药物组合物 |
CN101152154A (zh) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | 盐酸决奈达隆口服药物组合物及其制备方法 |
CN102188417A (zh) * | 2010-03-19 | 2011-09-21 | 江苏恒瑞医药股份有限公司 | 决奈达隆药物组合物 |
WO2011132167A1 (en) * | 2010-04-21 | 2011-10-27 | Sanofi-Aventis | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103054820A (zh) * | 2012-08-22 | 2013-04-24 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸决奈达隆药物组合物及其制备方法 |
CN105412027A (zh) * | 2015-11-13 | 2016-03-23 | 青岛市海慈医疗集团 | 一种盐酸决奈达隆片剂的制备方法 |
CN105412027B (zh) * | 2015-11-13 | 2018-10-26 | 青岛市海慈医疗集团 | 一种盐酸决奈达隆片剂的制备方法 |
CN108042489A (zh) * | 2017-12-19 | 2018-05-18 | 佛山市弘泰药物研发有限公司 | 一种盐酸决奈达隆自微乳制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102349889B (zh) | 2013-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4773456B2 (ja) | 生体利用率を向上させた経口用製剤 | |
TWI414321B (zh) | Solid preparation of enteric solid dispersion and method for producing the same | |
RU2417084C2 (ru) | Составы, содержащие базедоксифен ацетат | |
RU2489149C2 (ru) | Стабилизированные аморфные формы иматиниба мезилата | |
CN102791271B (zh) | 抗凝剂的溶出改善方法 | |
CN102946869A (zh) | γ-羟基丁酸的速释制剂及剂型 | |
CN102633777B (zh) | 达比加群酯2-酮戊二酸盐及其制备方法和应用 | |
CA2662265A1 (en) | Imatinib compositions | |
CN104650091A (zh) | 替格瑞洛的微粉化及其晶型,以及制备方法和药物应用 | |
CN103304539A (zh) | 达比加群酯苹果酸盐及其制备方法和应用 | |
EP3003277B1 (en) | Process for the preparation of a pharmaceutical composition comprising rivaroxaban | |
CN111670035A (zh) | 经口制剂及其用途 | |
JP2020518611A (ja) | 水溶解度及びバイオアベイラビリティが改善された組成物 | |
CN102349889B (zh) | 一种含有决奈达隆的组合物 | |
TWI784575B (zh) | 一種複合物的藥物組合物及其製備方法 | |
EP2050436A1 (en) | Pharmaceutical composition containing dutasteride | |
JP5721093B2 (ja) | 崩壊錠 | |
CN109963565B (zh) | 一种药物组合物及其制备方法 | |
WO2023213878A1 (en) | Solid tablet dosage form of ridinilazole | |
US20220226249A1 (en) | Solid tablet dosage form of ridinilazole | |
EP3996688B1 (en) | Pharmaceutical preparation | |
CN108721239A (zh) | 一种治疗阿尔茨海默病的缓释制剂及其制备方法 | |
JPH10226644A (ja) | 医薬組成物 | |
WO2024153130A1 (zh) | 一种包含并环化合物的药物组合物及其制备方法和应用 | |
JP4993274B2 (ja) | フェノフィブラート含有製剤組成物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant after: Jiangsu Simcere Pharmaceutical Research Company Limited Address before: 210042 -18, Xuanwu Avenue, Xuanwu District, Jiangsu, Nanjing, 669 Applicant before: Jiangsu Simcere Pharmaceutical Research Company Limited |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BODA PHARMACEUTICAL CO., LTD., JILIN PROVINCE Free format text: FORMER OWNER: JIANGSU SIMCERE PHARMACEUTICAL RESEARCH COMPANY LIMITED Effective date: 20140513 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210042 NANJING, JIANGSU PROVINCE TO: 136200 LIAOYUAN, JILIN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140513 Address after: 136200 Liaoyuan Province Economic Development Zone, Jilin, fortune road, No. 58, No. Patentee after: Jilin Boda Pharmaceutical Co.,Ltd. Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee before: Jiangsu Simcere Pharmaceutical Research Company Limited |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 136200 Liaoyuan Province Economic Development Zone, Jilin, fortune road, No. 58, No. Patentee after: Jilin Boda pharmaceutical Limited by Share Ltd Address before: 136200 Liaoyuan Province Economic Development Zone, Jilin, fortune road, No. 58, No. Patentee before: Jilin Boda Pharmaceutical Co.,Ltd. |